Effectiveness of Influenza Vaccination for Individuals with Chronic Obstructive Pulmonary Disease (COPD) in Low- and Middle-Income Countries

被引:20
作者
Lall, Dorothy [1 ]
Cason, Emily [2 ]
Pasquel, Francisco J. [3 ]
Ali, Mohammed K. [1 ]
Narayan, K. M. Venkat [2 ]
机构
[1] Inst Publ Hlth, Bengaluru, India
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
Chronic Obstructive Pulmonary Disease (COPD); influenza vaccine; effectiveness; low and middle income countries; CHRONIC RESPIRATORY-DISEASE; CHRONIC LUNG-DISEASE; PNEUMOCOCCAL VACCINATION; ACUTE EXACERBATION; VIRUS VACCINES; LIVE; MORTALITY; EFFICACY; DETERMINANTS; METAANALYSIS;
D O I
10.3109/15412555.2015.1043518
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
100201 [内科学];
摘要
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death globally. In addition to the mortality associated with it, people with COPD experience significant morbidity, making this set of conditions a major public health concern. Infections caused by influenza virus are a preventable cause of morbidity and vaccination has been shown to be effective. The evidence of their benefit in persons with COPD mainly comes from high-income countries where influenza vaccination is used in routine practice, but little is known about the effectiveness, cost-effectiveness, and scalability of vaccination in low- and middle-income countries.We therefore systematically reviewed and present evidence related to vaccination against influenza in persons with COPD with a special focus on studies from low- and middle-income countries (LMICs). Available data from 19 studies suggest that the use of influenza vaccine in persons with COPD is beneficial, cost-effective, and may be relevant for low- and middle-income countries. Wider implementation of this intervention needs to take into account the health care delivery systems of LMICs and use of prevalent viral strains in vaccines to be most cost effective.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 43 条
[1]
The role of nasal IgA in children vaccinated with live attenuated influenza vaccine [J].
Ambrose, Christopher S. ;
Wu, Xionghua ;
Jones, Taff ;
Mallory, Raburn M. .
VACCINE, 2012, 30 (48) :6794-6801
[2]
Anar C, 2010, NEW MICROBIOL, V33, P117
[3]
Ayabe Eriko, 2008, Nihon Kokyuki Gakkai Zasshi, V46, P511
[4]
Bartsch P, 1977, Dev Biol Stand, V39, P113
[5]
Efficacy and effectiveness of seasonal and pandemic A (HI NI) 2009 influenza vaccines in low and middle income countries: A systematic review and meta-analysis [J].
Breteler, Janna K. ;
Tam, John S. ;
Jit, Mark ;
Ket, Johannes C. F. ;
De Boer, Michiel R. .
VACCINE, 2013, 31 (45) :5168-5177
[6]
COPD exacerbations: definitions and classifications [J].
Burge, S ;
Wedzicha, JA .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 :46S-53S
[7]
Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease A secondary analysis of the multipurpose ISTAT survey on health and health care use [J].
Chiatti, Carlos ;
Barbadoro, Pamela ;
Marigliano, Anna ;
Ricciardi, Alessandra ;
Di Stanislao, Francesco ;
Prospero, Emilia .
HUMAN VACCINES, 2011, 7 (10) :1021-1025
[8]
The immunogenicity of intradermal influenza vaccination in COPD patients [J].
Chuaychoo, Benjamas ;
Wongsurakiat, Phunsup ;
Nana, Arth ;
Kositanont, Uraiwan ;
Maranetra, Khun Nanta .
VACCINE, 2010, 28 (24) :4045-4051
[9]
Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate [J].
Ciblak, Meral Akcay ;
Platformu, Grip .
VACCINE, 2013, 31 (03) :518-523
[10]
FELL PJ, 1977, LANCET, V1, P1282